The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMarwyn Value 16 Regulatory News (MVIR)

Share Price Information for Marwyn Value 16 (MVIR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 233.00
Bid: 200.00
Ask: 266.00
Change: 0.00 (0.00%)
Spread: 66.00 (33.00%)
Open: 233.00
High: 233.00
Low: 233.00
Prev. Close: 233.00
MVIR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Investment Update

7 Sep 2021 17:06

RNS Number : 0298L
Marwyn Value Investors Limited
07 September 2021
 

 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN, ANY MEMBER STATE OF THE EUROPEAN ECONOMIC AREA OR ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO

 

 

LEI: 213800L5751QTTVEA774

 

7 September 2021

 

 

Marwyn Value Investors Limited

Investment Update

 

Potential Settlement of VAT Reclaim

In November 2012, an underlying investment of Marwyn Value Investors LP (the "Master Fund"), Le Chameau Group plc ("LCG") (formerly Marwyn Management Partners Plc) sold its holding in Praesepe plc, a company operating in the gaming industry.

 

At the time of the sale there was an ongoing dispute between the gaming industry and HMRC on the principle of fiscal neutrality. The basis of the dispute was that some similar forms of gambling were treated differently for VAT purposes and test cases were pursued by The Rank Group Plc and Done Brothers (Cash Betting) Ltd.

 

Based on these test cases, Deloitte LLP and PricewaterhouseCoopers LLP were engaged by Praesepe plc to submit VAT reclaims to HMRC on a contingent fee basis. Certain of these VAT reclaims relate to the period of LCG's ownership and as such, under the terms of the sale agreement, a subsidiary of LCG retained a beneficial interest in the VAT reclaims that related to the period of LCG's ownership. The existence of this contingent VAT reclaim was disclosed in the historic financial statements of LCG which are publicly available. This contingent asset was transferred in 2020 to the Master Fund as part settlement of the outstanding loan between the LCG group and MVI LP.

 

The Praesepe VAT reclaims stood behind The Rank Group Plc claim ("Rank 2"). On 30 June 2021, the First-tier Tribunal ruled in favour of The Rank Group Plc and then on 25 August 2021, HMRC publicly confirmed that it will not appeal the decision made by the First-tier Tribunal. Based on this latest development, it is now anticipated that following due process, the Praesepe VAT reclaims sitting behind the Rank 2 claim will be paid by HMRC, which is expected to result in a cash payment to the Master Fund.

 

No amount has previously been recognised in either the annual historic LCG financial statements, or subsequently in the Net Asset Value ("NAV") of the Master Fund attributable to the Company due to the high level of uncertainty surrounding the likelihood of any receipt. It is not anticipated that the impact of settlement of the VAT reclaims, after deduction of contingent fees, taxes and other expenses, will be materially more than 5% of the most recently published NAV of either the Company's ordinary shares or realisation shares, however, there remains no certainty over the value of the VAT reclaims that will be repaid by HMRC, nor the timing of receipt of any such VAT reclaims. No amount will be reflected in the Company's estimated NAV calculations which are reported via RNS until there is sufficient certainty over the amount receivable.

 

Update on Zegona Return of Capital

In May 2021, Zegona Communications plc ("Zegona") announced its intention to return £335 million to its shareholders in cash, following receipt of the proceeds from the proposed acquisition of Euskaltel by MasMovil. In August 2021, Zegona confirmed that this capital return will be effected by way of a tender offer, to be completed in October 2021 at a price of £1.535 per Zegona share. The carrying value of Zegona in the latest estimated NAV published by the Company (as at 20 August 2021) was £1.51 per share, contributing to a total ordinary share NAV of £101.7 million (£1.822 per ordinary share) and a total realisation share NAV of £8.5 million (£2.300 per realisation share). The resulting increase in Zegona's carrying value will be approximately £0.75 million attributable to the Company's ordinary shares and £0.11 million attributable to the Company's realisation shares.

 

Zegona shareholders are entitled to sell approximately 98.0% of their shareholding (the "Tender Offer Entitlement"). Zegona shareholders may tender more than their Tender Offer Entitlement and will be allocated an additional pro rata portion of any Tender Offer Entitlement not taken up by other shareholders.

 

The sale of those shares representing the Tender Offer Entitlement will result in proceeds of approximately £45.4 million attributable to the Company's ordinary shares, representing £0.812 per share and approximately £6.7 million attributable to the Company's realisation shares, representing £1.812 per share and will generate a 1.4x return for the Marwyn Funds over the life of our investment. Amounts payable by Zegona under the tender offer are due to be received by 14 October 2021.

 

Returns to the Company's shareholders

The amount of the tender offer proceeds and any cash that is ultimately received relating to the Praesepe VAT reclaims that is attributable to the Company's realisation shareholders will be paid to realisation shareholders in due course following receipt.

 

As the Company has already returned significantly in excess of the 50% of net capital gains as set out in the Ordinary Share Distribution Policy, no cash return is due to ordinary shareholders from either the Zegona tender offer or any cash that may be received relating to the Praesepe VAT reclaim. Any such amounts will be retained by the Master Fund to support its acquisition vehicles and take advantage of the significant opportunity presented through a strong pipeline of potential acquisition targets, in line with the fund's investment strategy.

 

Company enquiries:

Aztec Financial Services (Jersey) Limited

Katrina Boult / Jenny Keen

Telephone: 01534 833000

 

Corporate broker:

Chris Clarke / Owen Matthews

Liberum Capital Limited

Telephone: 020 3100 2200

 

PR enquiries:

Alex Child-Villiers / Will Barker

Temple Bar Advisory Limited

Telephone: 07795 425580 / 07827 960151

 

Marwyn Value Investors Limited is a closed-ended investment company on the London Stock Exchange Specialist Fund Segment - a fully regulated market for professional, institutional and sophisticated investors. Current investments through its underlying funds include Zegona Communications plc, AdvancedAdvT Limited, Marwyn Acquisition Company plc, Marwyn Acquisition Company II Limited, Marwyn Acquisition Company III Limited and the operating business of Le Chameau.

For further information see http://www.marwynvalue.com. Neither the content of the Company's website, nor the content on any website accessible from hyperlinks on its website for any other website, is incorporated into, or forms part of, this announcement nor, unless previously published by means of a recognised information service, should any such content be relied upon in reaching a decision as to whether or not to acquire, continue to hold, or dispose of, securities in the Company.

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This announcement includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "expects", "believes", "estimates", "envisages", "plans", "anticipates", "targets", "aims", "continues", "expects", "intends", "hopes", "may", "will", "would", "could" or "should" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include matters that are not facts. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances. A number of factors could cause actual results and developments to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this announcement based on past trends or activities should not be taken as a representation that such trends or activities will continue in the future. Subject to any requirement under the Listing Rules, Prospectus Rules, the Disclosure Guidance and Transparency Rules or other applicable legislation or regulation, the Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should not place undue reliance on forward-looking statements, which speak only as of the date of this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUPUCUBUPGGQM
Date   Source Headline
2nd May 202410:05 amRNSNet Asset Value - 2016 Realisation Shares
22nd Apr 202411:00 amRNSNet Asset Values
15th Apr 202411:00 amRNSNet Asset Values
9th Apr 202410:05 amRNSNet Asset Value - 2016 Realisation Shares
18th Mar 202411:00 amRNSNet Asset Values
11th Mar 202411:00 amRNSNet Asset Values
4th Mar 202410:05 amRNSNet Asset Value - 2016 Realisation Shares
28th Feb 202410:05 amRNSNet Asset Value - 2016 Realisation Shares
23rd Feb 202410:05 amRNSNet Asset Value - 2016 Realisation Shares
14th Feb 202410:05 amRNSNet Asset Value - 2016 Realisation Shares
2nd Feb 202410:05 amRNSNet Asset Value - 2016 Realisation Shares
26th Jan 202410:05 amRNSNet Asset Value - 2016 Realisation Shares
15th Jan 202410:05 amRNSNet Asset Value - 2016 Realisation Shares
29th Dec 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
22nd Dec 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
14th Dec 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
1st Dec 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
24th Nov 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
14th Nov 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
3rd Nov 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
27th Oct 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
20th Oct 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
13th Oct 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
6th Oct 202310:32 amRNSPartial Cash Redemption of 2016 Realisation Shares
29th Sep 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
22nd Sep 202310:06 amRNS2016 Realisation Share Redemption
22nd Sep 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
14th Sep 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
8th Sep 20237:00 amRNSDistribution to 2016 Realisation Shareholders
4th Sep 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
25th Aug 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
14th Aug 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
4th Aug 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
28th Jul 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
21st Jul 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
14th Jul 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
7th Jul 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
30th Jun 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
23rd Jun 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
14th Jun 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
2nd Jun 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
26th May 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
12th May 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
5th May 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
28th Apr 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
18th Apr 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
11th Apr 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
31st Mar 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
24th Mar 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
14th Mar 202310:05 amRNSNet Asset Value - 2016 Realisation Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.